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　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　Abstract
A53－year－01d　woman　who　was　hypoxemic　due　to　primaly　lung　adenocarcinoma　with　both　pleuritis　and
pericarditis　carcinomatosa　was　treated　with　gefit㎞b，　an　inhibitor　of　the　epithelial　growth　factor　receptor
（EGFR）砂rQsine㎞ase。　The㎞or　seemed　to　produce皿ucin　because宙e　ex廿emely　high　se㎜KL－6　and
almost　nomlal　SP－D　va！ues　on　admission．　After　3　days　of　treatment，　the　patient　became　asymptomatic　and
oxygen　was　discontinued．　The　response　to　this面g　was　remarkable　on　chest　CT　findings．　Mucin
overproduction　could　offer　a　candidate　marker　to　detemユine　the　patient　subset　displaying　good　response　to
gefitirlib．
　　A53－year－old　woman　was．　referred　in　June　2004　with
abno㎜al　shadows　on　chest　radiography　and　was
admitted．　The　patient　reported　palpitations　and
breath！essness　over　the　preceding　10　days，　and　was　a
never－smoker．　Her　mother　had　died　of　interstitial
pne㎜onia．　Hypoxemia　was　identified　and　oxygen
therapy　was　started　i皿mediately．　Chest　computed
tomography（CT）（Fig．1A，　B）revealed　both　pericardial
and　pleural　effusion，　aエound　nodule　in　the　left　lower
lobe　of　the　lung，　and　hilar　and　mediastinal　lymph　node
swelling．　Consolidation　was　noted　with　CT　angiogram
and　air　bronchogram　signs　in　廿1e　left　upPer　lobe，
appe㎞g　cQmpatible　with　a　bronchiQ！oab1eolar
carcinoma　component．　Serum　CEA　level　was　high，　at
471・8ng／ml．　Se㎜鳳一61evel　was　4858　U／ml，　whch
was　extre皿ely　high，　whereas　SP－D　level　was　121・2
ng／ml，　slightly　above　nonnal　range．　The　day　after
admission，750　ml　of　pericardial　fluid　was　drained．
Cytology　yielded　positive　results　for　adenocarcinoma
cells　in　the　sputum，　and　in　pleural　and　pericardial　fluids．
Stage］V（T4N2M1）adenocarcinoma　of　the　Iung　was
diagnosed，　with　　a　possib！e　　bronchioloalveolar
component．　Gefitinib，　an　inhibitor　of　the　epithehal
growth　factor　receptor（EGFR）tyros血e　kinase　was
started　on　hospit l　day　6　at　2．50　mg／day，　and　response
was㎞press ve．．　After　3　days　of　treatment，　the　patient
became　asymptomatic　and　oxygerl　was　discontinued．
Chest　CT　on　day　180f　treatment（Fig．1C，　D）revealed
marked　impr vem nts　to　initial　findings．　On　day　280f
廿ea血 n ，　se㎜CEA　was　322・4ng／ml㎝d　se㎜KL－
6was　1982　U／mユ．
Se㎜1仙一60 feエs　a　c1血ic温ly　use蝕l　maエker　for
detecting　i terstitial　pneumonia，　and　reportedly
represents　MUC1，　a　member　of　mucin　glycoproteins．　In
出epresent cas ，　se㎜KL－6　was　high　on　a伽ission
and　decreased　in　respQnse　to　gefitinib，　with　concomitant
㎞provements血CT　find血gs．　High　se㎜Kし一6　thus
see s　attributable　to　overproduction　by　the　lung　cancer
itself．　The　importance　of　EGFR　members　in　cell
prohferation，　decreasing　apoptosis　and　angiogenesis　is
well recognized　in　various　solid　tumours．　Gefitinib　was
recently　approved　for　the　treatment　of　non．sma11－cell
lung　c ncer（NSCLC）．　However，　this　drug　is　only
effec廿ve　for　a　subset　of　NSCLC　patients．　Large－scale
studies　have　shown　that　pre1才ea㎞ent　characteristics　for
radiographic　improvement　include　being　Japanese，
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female，　a　nevel－smoker　and　patholo．gical　type　of
aderlocarcinoma，　particularly　with　a　bronchioloalveolar
sub噴〕e．l　The　present　patient　displayed　overproduction
of　KL－6　in　addition　to　all　of　these　charactenstics．　The
EGFR　system　has　been　shQwn　to　regu！ate　muc血
production，2　and　MUCl　irlteracts　with　EGFR　and
activates　the　EGFR　system，3　These　may　implicate
mucins　as　autoc血e　ligands　for｛he　EGFR　system．　A
subset　of　patients　with　NSCLC　has　recently　been
reported　to　display　specific　mutations　in　the　EGFR
genes，　corτelat血g　to　chnical　responsiveness　to　gefitinib．4
Howeveエ，　to　obtain　sufficient　tumour　samples　for　gene－
evaluation　is　sometimes　clinically　difficult．　Muc血
overproduction　could　offer　a　candidate　marker　to
dete㎜ine出e　patient　subset　displaying　good　response　to
gefit血ib，　al血ough　fし曲er　studies　aエe　clearly　needed，
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Figure　1：Contrast－enhanced　CT　of　the　chest．
A，B）CT　on　admission　revealed　massive　pericardia！effusion，　bilateral　pleural　effusion，　consolidation　with　CT
angiogram　and　ahl　bronchogram　signs　in　the　left　upper　lobe，　a　nodule　in　the　left　lower　lobe，　and　hilar　and　mediastinal
lymph　node　swelling．　C，　D）On　day　180f　gefitinib　treatment，　consohdation　in　the　left　upper　lobe　and　both　pleural　and
pericardial　effusion　had　resolved．　The　nodule　in　the　left　lower　lobe　and　lymph　nodes　became　much　smaller．
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